SLC5A2 and atherosclerosis: These results added to the growing evidence suggesting the favorable safety profile of SGLT2 inhibitors and aligned with previous findings of cardiorenal benefits of SGLT2 inhibitors among individuals with established ASCVD and CKD (Toyama et al., 2019; Bhattarai et al., 2022).